Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer

Overview of attention for article published in Einstein (São Paulo), May 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,924 followers.

RT @journaleinstein: This study evaluated the quality-adjusted time with and without symptoms or toxicity of #adotrastuzumabemtansine in th…

RT @journaleinstein: This study evaluated the quality-adjusted time with and without symptoms or toxicity of #adotrastuzumabemtansine in th…

This study evaluated the quality-adjusted time with and without symptoms or toxicity of #adotrastuzumabemtansine in the adjuvant setting compared to #trastuzumab for residual invasive #HER2 positive #breastcancer. Learn more at: https://t.co/IaZijHEicm #

New article: Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer https://t.co/aAvIdzxOIQ #breastcancer #oncology https://t.co/HajuTr2NiC

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.